Amid the challenges of a global pandemic, parts of the medtech sector were positioned to reap some of the spoils enjoyed by the big pharma players. Huge demand for Covid assays boosted revenues to previously unanticipated heights and each new wave and variant provided new opportunities for innovation. As the pandemic recedes, the demand for…
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…
Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…
In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…
In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…
Evaluate Pharma®ワールドプレビュー2021 2026年への展望 製薬業界動向レポートの分析ハイライトを、インフォグラフィックでご覧いただけます。 製薬業界…
製薬業界動向レポート2021 Evaluate Pharma®ワールドプレビュー2021 2026年への展望…
We provide top-level insights and analyses on all the key trends in the fourteenth edition of the Evaluate Pharma World Preview 2021, Outlook to 2026 report. Our most…
This infographic showcases the key insights from the Evaluate Pharma World Preview, Outlook to 2026 report, at a time when the biopharma sector is under intense…
